Relationship between nephrotoxicity and area under the concentration–time curve of vancomycin in critically ill patients: a multicenter retrospective study

Author:

Ishigo Tomoyuki1ORCID,Matsumoto Kazuaki2ORCID,Yoshida Hiroaki3,Tanaka Hiroaki3,Ibe Yuta1,Fujii Satoshi1ORCID,Fukudo Masahide1,Fujihara Hisato45,Yamaguchi Fumihiro6,Ebihara Fumiya7,Maruyama Takumi7,Hamada Yukihiro78,Samura Masaru29ORCID,Nagumoi Fumio9,Komatsu Toshiaki10ORCID,Tomizawa Atsushi10,Takuma Akitoshi511,Chiba Hiroaki12,Nishi Yoshifumi13,Enoki Yuki2ORCID,Taguchi Kazuaki2,Suzuki Ayako4

Affiliation:

1. Department of Pharmacy, Sapporo Medical University Hospital, Sapporo, Japan

2. Division of Pharmacodynamics, Keio University Faculty of Pharmacy, Tokyo, Japan

3. Department of Pharmacy, Kyorin University Hospital, Mitaka, Japan

4. Department of Pharmacy, Showa University Fujigaoka Hospital, Yokohama, Japan

5. Department of Hospital Pharmaceutics, School of Pharmacy, Showa University, Tokyo, Japan

6. Department of Respiratory Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan

7. Department of Pharmacy, Tokyo Women’s Medical University Hospital, Tokyo, Japan

8. Department of Pharmacy, Kochi Medical School Hospital, Kochi, Japan

9. Department of Pharmacy, Yokohama General Hospital, Yokohama, Japan

10. Department of Pharmacy, Kitasato University Hospital, Sagamihara, Japan

11. Department of Pharmacy, Showa University Northern Yokohama Hospital, Yokohama, Japan

12. Department of Pharmacy, Tohoku Kosai Hospital, Sendai, Japan

13. Center for Pharmacist Education, School of Pharmacy, Nihon University, Funabashi, Japan

Abstract

ABSTRACT We aimed to assess the frequency of acute kidney injury (AKI) in different areas under the concentration–time curve (AUC) values of vancomycin (VAN) using a two-point blood collection method, allowing for accurate AUC assessment in critically ill patients. This multicenter retrospective observational study was conducted in eight hospitals. We retrospectively analyzed the data of patients who had received VAN in an intensive care unit (ICU) between January 2020 and December 2022. The primary outcome was the incidence of AKI. Patients were classified into three groups according to the AUC 24–48h at the initial therapeutic drug monitoring (TDM) as follows: <500, 500–600, and ≥600 µg·h/mL. The AUC 24–48h values were calculated using the Bayesian estimation software Practical AUC-guided TDM. Among 146 patients [median age (interquartile range), 67 (56–78) years; 39% women], the AUC 24–48h <500 µg·h/mL had an AKI rate of 6.5% (7/107), the AUC 24–48h 500–600 µg·h/mL had an AKI rate of 28.0% (7/25), and the AUC 24–48h ≥600 µg·h/mL had an AKI rate of 42.9% (6/14). In multivariate Cox proportional hazard analysis, the AUC 24–48h 500–600 µg·h/mL [hazard ratio 5.4, 95% confidence interval (CI) 1.64–17.63] and the AUC 24–48h ≥600 μg·h/mL (hazard ratio 7.0, 95% CI 2.31–21.18) significantly correlated with a higher incidence of AKI compared with the AUC 24-48h <500 μg·h/mL. In conclusion, we identified an association between AUC on day 2 and the risk of AKI in ICU patients, suggesting that not only AUCs above 600 µg·h/mL but also those between 500 and 600 µg·h/mL pose a risk for AKI. IMPORTANCE Vancomycin (VAN) is a glycopeptide antibiotic and one of the most commonly used antibiotics for severe infections caused by methicillin-resistant Staphylococcus aureus . However, higher VAN concentrations have been associated with an increased risk of acute kidney injury (AKI). Herein, we aimed to assess the frequency of AKI in different areas under the concentration–time curve (AUC) values of VAN using a two-point blood collection method, allowing for accurate AUC assessment in critically ill patients. We identified an association between AUC on day 2 and the risk of AKI in intensive care unit patients, suggesting that not only AUCs above 600 µg·h/mL but also those between 500 and 600 µg·h/mL pose a risk for AKI. Therefore, individualized dosing is feasible, with pharmacists being able to optimize VAN doses to attain appropriate targets.

Funder

Meiji Seika Pharma

Dainippon Sumitomo Pharma

Shionogi

Publisher

American Society for Microbiology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3